USPTO granted patent US12594007B2 to Circius Pharma AB on April 7, 2026. The patent covers an energy transmitting device and system for monitoring and treating tinnitus via bone conduction, comprising a first unit that produces treatment energy and a second unit that secures the first unit against the patient's skin. The device transmits energy through bone conductivity for tinnitus treatment. Assignee is Circius Pharma AB with inventors including Peter Arndt, Fredrik Westman, Arash Golshenas, and Ali Jehanfard. The patent contains 21 claims.

This is a patent grant notice with no compliance obligations. Entities developing competing tinnitus treatment devices should review the patent claims to assess potential infringement risks. Medical device manufacturers and pharmaceutical companies in the hearing/healthcare sector should consider this intellectual property when designing bone conduction or tinnitus treatment products.